CGRP antagonists and antibodies for the treatment of migraine

Expert Opinion on Investigational Drugs

Volumn 24, Issue 1, 2015, Pages 31-41

  Vécsei, László ^a   Szok, Délia ^a   Csáti, Anett ^a   Tajti, János ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Anti calcitonin gene related peptide mAbs; Anti calcitonin gene related peptide receptor mAbs; Calcitonin gene related peptide; Calcitonin gene related peptide receptor antagonists; Calcitonin gene related peptide receptors; Migraine treatment

Indexed keywords

ANTIBODY; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; MONOCLONAL ANTIBODY; OLCEGEPANT;

DRUG EFFICACY; DRUG MECHANISM; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; MIGRAINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84916631352     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.960921     Document Type: Review

References (98)

1. Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev 2005;48:438-56
2. Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004;44(Suppl 1):S20-30
3. Vollbracht S, Rapoport AM. The pipeline in headache therapy. CNS Drugs 2013;27:717-29
4. Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related Peptide activity. CNS Drugs 2014;28:389-99
5. Edvinsson L. Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci 1985;8:126-31
6. Poyner DR. Molecular pharmacology of receptors for calcitonin-gene-related peptide, amylin and adrenomedullin. Biochem Soc Trans 1997;25:1032-6
7. Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol 1997;11:167-239
8. Alevizaki M, Shiraishi A, Rassool FV, et al. The calcitonin-like sequence of the beta CGRP gene. FEBS Lett 1986;206:47-52
9. Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the Phase 1 program. Cephalalgia 2013;34:483-92
10. Terenghi G, Polak JM, Ghatei MA, et al. Distribution and origin of calcitonin gene-related peptide (CGRP) immunoreactivity in the sensory innervation of the mammalian eye. J Comp Neurol 1985;233:506-16
11. Emeson RB, Hedjran F, Yeakley JM, et al. Alternative production of calcitonin and CGRP mRNA is regulated at the calcitonin-specific splice acceptor. Nature 1989;341:76-80
12. Tippins JR, Di Marzo V, Panico M, et al. Investigation of the structure/activity relationship of human calcitonin gene-related peptide (CGRP). Biochem Biophys Res Commun 1986;134:1306-11
13. Morris HR, Panico M, Etienne T, et al. Isolation and characterization of human calcitonin gene-related peptide. Nature 1984;308:746-8
14. Miranda LP, Shi L, Holder JR, et al. Peptide antagonists of the calcitonin gene-related peptide (CGRP) receptor with improved pharmacokinetics and pharmacodynamics. Biopolymers 2013;100:422-30
15. Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010;169:683-96
16. Tajti J, Uddman R, Moller S, et al. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999;76:176-83
17. Edvinsson L, Mulder H, Goadsby PJ, Uddman R. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J Auton Nerv Syst 1998;70:15-22
18. Hou M, Uddman R, Tajti J, Edvinsson L. Nociceptin immunoreactivity and receptor mRNA in the human trigeminal ganglion. Brain Res 2003;964:179-86
19. Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain 2014;137:650-1
20. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-6
21. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7
22. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54-61
23. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573-82
24. Edvinsson L, Villalon CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther 2012;136:319-33
25. Csati A, Tajti J, Tuka B, et al. Calcitonin gene-related peptide and its receptor components in the human sphenopalatine ganglion - interaction with the sensory system. Brain Res 2012;1435:29-39
26. Thalakoti S, Patil VV, Damodaram S, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 2007;47:1008-23; discussion 24-5
27. Tajti J, Uddman R, Edvinsson L. Neuropeptide localization in the "migraine generator" region of the human brainstem. Cephalalgia 2001;21:96-101
28. Kageneck C, Nixdorf-Bergweiler BE, Messlinger K, Fischer MJ. Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate. J Headache Pain 2014;15:7
29. Hay DL, Poyner DR, Quirion R. International Union of Pharmacology. LXIX. Status of the calcitonin generelated peptide subtype 2 receptor. Pharmacol Rev 2008;60:143-5
30. Heroux M, Hogue M, Lemieux S, Bouvier M. Functional calcitonin generelated peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activitymodifying protein-1. J Biol Chem 2007;282:31610-20
31. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393:333-9
32. Evans BN, Rosenblatt MI, Mnayer LO, et al. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 2000;275:31438-43
33. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Ther 2006;109:173-97
34. Moore EL, Salvatore CA. Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. Br J Pharmacol 2012;166:66-78
35. Fitzsimmons TJ, Zhao X, Wank SA. The extracellular domain of receptor activitymodifying protein 1 is sufficient for calcitonin receptor-like receptor function. J Biol Chem 2003;278:14313-20
36. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002;54:233-46
37. Villalon CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 2009;124:309-23
38. ter Haar E, Koth CM, Abdul-Manan N, et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure 2010;18:1083-93
39. Koth CM, Abdul-Manan N, Lepre CA, et al. Refolding and characterization of a soluble ectodomain complex of the calcitonin gene-related peptide receptor. Biochemistry 2010;49:1862-72
40. Eftekhari S, Salvatore CA, Gaspar RC, et al. Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex. Cerebellum 2013;12:937-49
41. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
42. Humphrey PP, Feniuk W, Perren MJ. Anti-migraine drugs in development: advances in serotonin receptor pharmacology. Headache 1990;30:12-16; discussion 24-8
43. Aiyar N, Daines RA, Disa J, et al. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J Pharmacol Exp Ther 2001;296:768-75
44. Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 2012;21:807-18
45. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129:420-3
46. Aiyar N, Rand K, Elshourbagy NA, et al. A cDNA encoding the calcitonin generelated peptide type 1 receptor. J Biol Chem 1996;271:11325-9
47. Iovino M, Feifel U, Yong CL, et al. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004;24:645-56
48. Joshi P, Anderson C, Binch H, et al. Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists. Bioorg Med Chem Lett 2014;24:845-9
49. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-10
50. Tvedskov JF, Tfelt-Hansen P, Petersen KA, et al. CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrateinduced migraine. Cephalalgia 2010;30:1346-53
51. Burgey CS, Paone DV, Shaw AW, et al. Synthesis of the (3R,6S)-3-amino-6-(2,3- difluorophenyl)azepan-2-one of telcagepant (MK-0974), a calcitonin gene-related peptide receptor antagonist for the treatment of migraine headache. Org Lett 2008;10:3235-8
52. Paone DV, Shaw AW, Nguyen DN, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3- difluorophenyl)-2-oxo-1- (2,2,2- trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3- dihydro-1H-imidazo[4,5-b]pyridin- 1-yl) piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50:5564-7
53. Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2- oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]- 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin generelated peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008;324:416-21
54. Moore EL, Burgey CS, Paone DV, et al. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine. Eur J Pharmacol 2009;602:250-4
55. Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther 2010;334:746-52
56. Edvinsson L, Chan KY, Eftekhari S, et al. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia 2010;30:1233-40
57. Han TH, Blanchard RL, Palcza J, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin generelated peptide receptor antagonist, in adults. J Clin Pharmacol 2010;50:1367-76
58. Depre M, Macleod C, Palcza J, et al. Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine. Cephalalgia 2013;33:1292-301
59. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-12
60. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK- 0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebocontrolled, parallel-treatment trial. Lancet 2008;372:2115-23
61. Edvinsson L, Ho TW. CGRP receptor antagonism and migraine. Neurotherapeutics 2010;7:164-75
62. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010;376:645-55
63. Ho AP, Dahlof CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 2010;30:1443-57
64. Hansen JM, Ashina M. Calcitonin generelated peptide and migraine with aura: a systematic review. Cephalalgia 2014;34:695-707
65. Bell IM, Gallicchio SN, Wood MR, et al. Discovery of MK-3207: a highly potent, orally bioavailable CGRP receptor antagonist. ACS Med Chem Lett 2010;1:24-9
66. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011;31:712-22
67. Peroutka SJ. Calcitonin gene-related Peptide targeted immunotherapy for migraine: progress and challenges in treating headache. BioDrugs 2014;28:237-44
68. Degnan AP, Chaturvedula PV, Conway CM, et al. Discovery of (R)-4- (8-fluoro-2-oxo-1,2-dihydroquinazolin-3 (4H)-yl)-N-(3-(7-methyl-1H-indazol-5 - yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin- 1-yl)propan-2-yl)piperidine-1-carboxami de (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 2008;51:4858-61
69. Luo G, Chen L, Conway CM, et al. Discovery of (5S,6S,9R)-5-amino-6-(2,3- difluorophenyl)-6,7,8,9-tetrahydro-5Hcyclohepta[ b]pyri din-9-yl 4-(2-oxo-2,3- dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem 2012;55:10644-51
70. Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014;34:114-25
71. Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011;31:573-84
72. Greco R, Mangione A, Siani F, et al. Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia 2013;34:594-604
73. Feistel S, Albrecht S, Messlinger K. The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion. J Headache Pain 2013;14:93
74. Chaturvedula PV, Mercer SE, Pin SS, et al. Discovery of (R)-N-(3-(7-methyl- 1H-indazol-5-yl)-1-(4-(1- methylpiperidin-4-yl)-1-oxopropan-2-y l)-4-(2-oxo-1,2-dihydroquinolin-3-yl) piperidine-1-carboxamide (BMS- 742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. Bioorg Med Chem Lett 2013;23:3157-61
75. Han X, Civiello RL, Conway CM, et al. The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2. Bioorg Med Chem Lett 2013;23:1870-3
76. Bell IM, Gallicchio SN, Stump CA, et al. [(11)C]MK-4232: the first positron emission tomography tracer for the calcitonin gene-related peptide receptor. ACS Med Chem Lett 2013;4:863-8
77. Hostetler ED, Joshi AD, Sanabria-Bohorquez S, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther 2013;347:478-86
78. Dostalek M, Gardner I, Gurbaxani BM, et al. Pharmacokinetics, pharmacodynamics and physiologicallybased pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 2013;52:83-124
79. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:493-507
80. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 2010;24:23-39
81. Steiner TJ, Catarci T, Hering R, et al. If migraine prophylaxis does not work, think about compliance. Cephalalgia 1994;14:463-4
82. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808
83. Vollbracht S, Rapoport AM. New treatments for headache. Neurol Sci 2014;35(Suppl 1):89-97
84. A safety, tolerability, and pharmacokinetic study of single, escalating subcutaneous doses of LY2951742 in healthy volunteers. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT01337596 [Accessed 17 June 2014]
85. de Hoon J MD, Vermeersch S, Van Hecken A, et al. Safety, pharmacokinetics, and pharmacodynamics of LY2951742: a monoclonal antibody targeting CGRP. 2013. Available from: http://cepsagepubcom/content/33/8-suppl/1fullpdf?html
86. A phase 2, randomized, double-blind, placebo-controlled study of LY2951742 in patients with migraine. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT01625988 [Accessed 17 June 2014]
87. A single-dose, placebo-controlled, ascending dose study to determine the safety, tolerability, and pharmacokinetics of ALD403, a humanized anti-calcitonin gene-related peptide monoclonal antibody administered by intravenous infusion and subcutaneous injection. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT01579383 [Accessed 17 June 2014]
88. A parallel group, soluble-blind, randomized, placebo controlled phase 1b trial to evaluate the safety, pharmacokinetics, and efficacy of a single dose of ALD403 administered intravenously in patients with frequent episodic migraines. http://wwwclinicaltrialsgov/ct2/show/NCT01772524 [Accessed 17 June 2014]
89. A randomized, placebo-controlled, double-blind, parallel group study assessing the safety, tolerability, and pharmacokinetics of two different doses of LBR-101 given intravenously and subcutaneously. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT01991509 [Accessed 17 June 2014]
90. A multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-dose study comparing the efficacy and safety of subcutaneous LBR-101 with placebo for the preventive treatment of chronic migraine. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT02021773 [Accessed 17 June 2014]
91. A multicenter, randomized, double-blind, placebo-controlled, parallel-group, study comparing the efficacy and safety of two doses of subcutaneous LBR-101 with placebo for the preventive treatment of high frequency episodic migraine. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT02025556 [Accessed 17 June 2014]
92. Bigal ME, Walter S, Bronson M, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR- 101, a monoclonal antibody against CGRP. Cephalalgia 2014. [Epub ahead of print]
93. Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs 2014;6:871-8
94. Walter S, Bronson M, Bigal ME. Assessment of Cardiovascular Safety in cynomolgus monkeys following IV administration of LBR-101. 2014 Annual Meeting; Philadelphia, PA; 2014
95. A phase I, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 334 in healthy subjects and migraine patients. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT01688739 [Accessed 17 June 2014]
96. Phase 1, randomized, double-blind, placebo-controlled, ascending multipledose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 334 in healthy subjects and in migraine patients. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT01723514 [Accessed 17 June 2014]
97. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AMG 334 in migraine prevention. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT01952574 [Accessed 17 June 2014]
98. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AMG 334 in chronic migraine prevention. Available from: http://wwwclinicaltrialsgov/ct2/show/NCT02066415 [Accessed 17 June 2014]